We are live on ! Find out more
Jacobs Levy Equity Management

Jacobs Levy Equity Management Portfolio holdings

AUM $23.8B
1-Year Est. Return 25.4%
This Fund
S&P 500
This Quarter Est. Return
+8.56%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$14.8B
AUM Growth
+$1.79B
Cap. Flow
+$849M
Cap. Flow %
5.76%
Top 10 Hldgs %
16.89%
Holding
1,178
New
178
Increased
473
Reduced
324
Closed
161

Top Sells

Rank Stock Value
1
QCOM icon
Qualcomm
QCOM
+$98.3M
2
TGT icon
Target
TGT
+$86.8M
3
OXY icon
Occidental Petroleum
OXY
+$74.7M
4
SYF icon
Synchrony
SYF
+$61.6M
5
ICE icon
Intercontinental Exchange
ICE
+$57.6M

Sector Composition

Rank Sector Weight
1 Technology 21.69%
2 Healthcare 13.54%
3 Financials 13.08%
4 Consumer Discretionary 12.97%
5 Communication Services 9.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WK icon
1126
Workiva
WK
$2.94B
-78,059
Closed -$6.89M
WMT icon
1127
Walmart Inc
WMT
$871B
-408,393
Closed -$18.5M
XCUR icon
1128
Exicure
XCUR
$11.2M
-730
Closed -$239K
XERS icon
1129
Xeris Biopharma Holdings
XERS
$1.44B
-162,321
Closed -$732K
MTVA
1130
MetaVia Inc
MTVA
$7.64M
-66
Closed -$762K
QVCGA
1131
DELISTED
QVC Group Inc Series A
QVCGA
-8,545
Closed -$5.03M
LGTY
1132
DELISTED
Logility Supply Chain Solutions, Inc. Common Stock
LGTY
-26,680
Closed -$552K
CUTR
1133
DELISTED
Cutera, Inc.
CUTR
-12,542
Closed -$377K
AGR
1134
DELISTED
Avangrid, Inc.
AGR
-24,517
Closed -$1.22M
MORF
1135
DELISTED
Morphic Holding, Inc. Common Stock
MORF
-35,514
Closed -$2.25M
SLCA
1136
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
-500,626
Closed -$6.15M
AFIB
1137
DELISTED
Acutus Medical Inc
AFIB
-93,471
Closed -$1.25M
PXD
1138
DELISTED
Pioneer Natural Resource Co.
PXD
-257,045
Closed -$40.8M
BFX
1139
DELISTED
BowFlex Inc.
BFX
-70,635
Closed -$1.1M
PRTK
1140
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
-63,210
Closed -$446K
AXLA
1141
DELISTED
Axcella Health Inc. Common Stock
AXLA
-5,164
Closed -$615K
FRBK
1142
DELISTED
Republic First Bancorp Inc
FRBK
-94,779
Closed -$357K
ACGN
1143
DELISTED
Aceragen Inc
ACGN
-13,264
Closed -$293K
SPPI
1144
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
-258,662
Closed -$843K
AUD
1145
DELISTED
Audacy, Inc.
AUD
-168,134
Closed -$883K
OYST
1146
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
-19,830
Closed -$362K
BIOR
1147
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
-368
Closed -$438K
CHRA
1148
DELISTED
Charah Solutions, Inc Common Stock
CHRA
-1,688
Closed -$82K
CYBE
1149
DELISTED
Cyberoptics Corp
CYBE
-11,299
Closed -$293K
TWTR
1150
DELISTED
Twitter, Inc.
TWTR
-105,408
Closed -$6.71M

Similar funds

Jacobs Levy Equity Management's Q2 2021 Portfolio in Review

As of Q2 2021, Jacobs Levy Equity Management held 1,178 positions worth $14.8B, up 14% from $13B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Jacobs Levy Equity Management deployed $849M of net new capital in Q2 2021, opening 178 new positions and adding to 473 existing holdings. Its largest new stake was Lam Research: 991,120 shares worth $64.5M.

By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 22% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Qualcomm, an estimated $98.3M trimmed.

  • Jacobs Levy Equity Management's largest Q2 2021 buy was Lam Research: 991,120 shares worth $64.5M.
  • Jacobs Levy Equity Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $128M increase.
  • Jacobs Levy Equity Management's biggest Q2 2021 reduction was Qualcomm, cutting an estimated $98.3M.
  • Jacobs Levy Equity Management fully exited Occidental Petroleum in Q2 2021, selling an estimated $74.7M.
  • Jacobs Levy Equity Management's ten largest holdings make up 17% of its $14.8B portfolio in Q2 2021.
  • Jacobs Levy Equity Management opened 178 new positions and closed 161 in Q2 2021.
  • Jacobs Levy Equity Management's portfolio value rose 14% quarter-over-quarter to $14.8B.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2021, filed 16 Aug 2021.